" Akontio " SRL
" Akontio " reported total assets of 69,650 € at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Dec 2025).
The score of " Akontio " shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -60 % Total assets -42 %
Accounts of the company itself (not consolidated).
The full file covers 6 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
" Akontio "'s annual accounts
Filed annual accounts
- Year ended 30 Jun 2025filed on 17 Dec 2025
- Year ended 30 Jun 2024filed on 30 Dec 2024
- Year ended 30 Jun 2023filed on 19 Dec 2023
- Year ended 30 Jun 2022filed on 12 Dec 2022
- Year ended 30 Jun 2021filed on 15 Dec 2021
" Akontio "'s financial analysis
- Solvency66.7%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of " Akontio "
" Akontio "'s publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0733.855.973
- VAT number
- BE0733855973
- Peppol
- Registered · 0208:0733855973 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Sep 2019
- Registered office
- 4500 Huy
- Latest accounts
- 2025 · filed on 17 Dec 2025
- Activity
- Research and experimental development on biotechnology (NACE 72101)
" Akontio " (SRL) has been based in Huy since 2019, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 17,955 € and equity of 46,472 €; its revenue is not published. Its solvency stands at 66.7%, above the median of its sector (58.2%).
Companies similar to " Akontio "
Companies in the same business, of comparable size and area, outside its group.
- MDSH Research and experimental development on natural sciences and engineering Ixelles · balance sheet 92,229 €
- Europharmedtech Research and experimental development on natural sciences and engineering Ganshoren · balance sheet 54,960 €
- Biograbbit Research and experimental development on natural sciences and engineering Dendermonde · balance sheet 61,503 €
- Biokey Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 2,606 €
- ComPro Pharma Research and experimental development on natural sciences and engineering Sprimont · balance sheet 76,879 €
- 1991 Southern Sky Research and experimental development on natural sciences and engineering Anderlecht · balance sheet 77,620 €
- Shift Happens Research and experimental development on natural sciences and engineering Ghent · balance sheet 62,809 €
- Herlinco Accounting, bookkeeping and auditing activities; tax consultancy Overijse · balance sheet 109,375 €
Frequently asked questions about " Akontio "
What is the revenue of " Akontio "?
" Akontio " files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of " Akontio "?
In Belgium, the VAT number is the company number prefixed with BE: BE0733855973 for " Akontio ", if the company is VAT-registered. Its company number (CBE) is 0733.855.973.
Where is the registered office of " Akontio "?
According to the CBE register, the registered office of " Akontio " is in 4500 Huy.
What is the equity of " Akontio "?
At the close of the 2025 financial year, the equity of " Akontio " amounts to 46,472 €, a solvency of 66.7% of total assets.
Who manages " Akontio "?
The register lists 1 active mandates at " Akontio ". Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of " Akontio "
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →